Novartis agreed to acquire Blackstone Life Sciences' Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company retakes control over a treatment candidate for blood clots it licensed to Anthos when the Boston-based firm was launched in 2019.
